Changes in Beneficial Ownership · 4

Inhibikase Therapeutics, Inc.

IKTNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jul 31, 2026Accepted Jul 31, 2026, 4:32 PM EDTFiling CIK 1750149Accession 0001231919-26-000815

View company →Permanent SEC source ↗

Structured filing — 4

form4-07312026_080714.xml

Open full document ↗

Filing details

Report period: 2026-07-29
Issuer: Inhibikase Therapeutics, Inc.
Issuer CIK: 0001750149
Trading symbol: IKT
No longer subject to Section 16: Checked

Reporting owner 1

Name: RA CAPITAL MANAGEMENT, L.P.
Reporting owner CIK: 0001346824
Relationship: 10% owner
Address: 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 2

Name: RA Capital Healthcare Fund LP
Reporting owner CIK: 0001315082
Relationship: 10% owner
Address: C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 3

Name: Kolchinsky Peter
Reporting owner CIK: 0001384859
Relationship: 10% owner
Address: C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Reporting owner 4

Name: Shah Rajeev M.
Reporting owner CIK: 0001619841
Relationship: 10% owner
Address: C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116

Non-derivative transactions

Non-derivative transactions · 1 reported row
Security	Transaction date	Code	Amount	A / D	Price (USD)	Owned after	Ownership	Nature of ownership
Common Stock	2026-07-29	J · Form 4^[F1]	18,030,000	D	^[F1]	6,970,000	I	See footnotes^[F2]^[F3]

Table key

J · Form 4: Other acquisition or disposition; see explanation
D: Disposed
I: Indirect

Derivative transactions

Derivative transactions · 1 reported row
Security	Conversion / exercise price (USD)	Transaction date	Code	Amount	A / D	Price (USD)	Exercisable	Expires	Underlying security	Underlying shares	Owned after	Ownership	Nature of ownership
Pre-Funded Warrant (Right to Buy)	0.001	2026-07-29	J · Form 4^[F1]	18,030,000	A	^[F1]	^[F4]	^[F4]	Common Stock	18,030,000	18,030,000	I	See footnotes^[F2]^[F3]

Table key

J · Form 4: Other acquisition or disposition; see explanation
A: Acquired
I: Indirect

Footnotes

F1: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").↩ 1 ↩ 2 ↩ 3 ↩ 4
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.↩ 1 ↩ 2
F3: Held directly by the Fund.↩ 1 ↩ 2
F4: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.↩ 1 ↩ 2

Signature 1

Signed: /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Date: 2026-07-31

Signature 2

Signed: /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
Date: 2026-07-31

Signature 3

Signed: /s/ Peter Kolchinsky, individually
Date: 2026-07-31

Signature 4

Signed: /s/ Rajeev Shah, individually
Date: 2026-07-31

Company context

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Current securities

IKTNASDAQ · EQUITY · Current

Get the free weekly BCS email.